Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8450242 | Experimental Cell Research | 2018 | 21 Pages |
Abstract
Different levels of nucleolin expression resulted in a 3.4-fold higher association of liposomes targeting nucleolin (functionalized with the nucleolin-binding F3 peptide) in U87, relative to GBM11 glioblastoma cells. Moreover, nucleolin was suggested as a potential marker in OCT4-, NANOG-positive GSC, and in the corresponding non-stem GBM cells, as well as in SOX2-positive GSC. Doxorubicin delivered by liposomes targeting nucleolin enabled a level of cytotoxicity that was 2.5- or 4.6-fold higher compared to the non-targeted counterparts. Importantly, an overexpression of nucleolin was also observed in cells of patient-derived samples, as compared with normal brain. Overall, these results suggested nucleolin as a therapeutic target in GBM.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Joana Balça-Silva, Anália do Carmo, HermÃnio Tão, Olinda Rebelo, Marcos Barbosa, Vivaldo Moura-Neto, Ana Bela Sarmento-Ribeiro, Maria Celeste Lopes, João Nuno Moreira,